Business Context and Reporting Period
This Form 6-K filing by ProQR Therapeutics N.V. covers the month of June 2026, specifically reporting on material definitive agreements entered into on June 25, 2026, with an expected closing date of June 26, 2026. The filing details a registered direct offering of ordinary shares and a concurrent private placement transaction.
Key Financial Metrics and Capital Structure
- Offering Size: 27,624,310 ordinary shares sold in a registered direct offering.
- Offering Price: $1.81 per share.
- Net Proceeds: Approximately $46.5 million from the registered direct offering after underwriting discounts and estimated expenses.
- Private Placement: 5,100,780 shares sold to Eli Lilly and Company at $1.81 per share, generating approximately $9.2 million.
- Total Capital Raised: Approximately $55.7 million combined from both transactions.
- Underwriters: BofA Securities, Inc., Evercore Group L.L.C., and Cantor Fitzgerald & Co.
Material Changes and Transactions
The primary material change is the significant increase in equity capital through the issuance of new shares. The company executed an Underwriting Agreement for the public offering and a separate Share Purchase Agreement with Eli Lilly and Company. The Lilly transaction includes a six-month lock-up period on the shares purchased, subject to the termination of the Amended and Restated Collaboration Agreement. Additionally, Lilly has agreed to a standstill on acquiring additional shares or proposing certain transactions.
Outlook, Risks, and Management Commentary
The filing does not provide specific forward-looking guidance, revenue projections, or management commentary regarding operational performance. The primary focus is on the execution of the capital raise. Risks associated with the transaction include customary closing conditions and the dilution of existing shareholders due to the issuance of approximately 32.7 million new shares. The private placement shares are subject to resale restrictions and registration rights.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $46.5 million net proceeds from the registered direct offering.
- Confirm the exact number of shares issued to Eli Lilly and the status of the six-month lock-up agreement.
- Review the impact of the new share issuance on total outstanding shares and potential dilution metrics.
- Assess the company's updated cash position post-closing to evaluate runway for clinical development.
- Check for any subsequent filings regarding the use of proceeds or changes to the collaboration agreement with Eli Lilly.